Taiwanese retrospective study (2001-2022) of 2,383 PsA pts Rx w/ 1+ DMARDs. Comparing 1,190 bDMARDs vs 1,193 cDMARD Rx pts, bDMARDs assoc. w/ signif lower risk of MACE (HR 0.65), all-cause mortality (0.44), CV mortality (0.54), but more infx related Hosp (1.45) https://t.co/eu7fSVkjZl

QD Clinics - Mission: APP Partners in Care Week 1 QD300: Flare or Beware (featuring Lindsay Tom, PA-C and Phong Nguyen, MD) QD301: CAR-T Cell Therapy for Lupus (featuring Philip Mease, MD and Cayla Alexander, DNP) QD302: Unweanable PMR (featuring Jack Cush, MD, and Leilani Law, https://t.co/Ow2KMAzwGK

ICYMI: MSK Evaluation https://t.co/QuHWcv6zAc https://t.co/0n5A1EtL9c

B Cell Targeting in Idiopathic Thrombocytopenic Purpura The New England Journal of Medicine has published a phase III clinical trial showing that a B cell targeting monoclonal antibody, ianalumab, was effective in more than half of the patients with primary immune https://t.co/VN0KjE478B

I Can't Believe it's Not Seronegative Rheumatoid Arthritis?! In rheumatology, we're no stranger to uncertainty. In any diagnosis of seronegative rheumatoid arthritis, it's always our invitation to reconsider the diagnosis. https://t.co/JGPTXkvF3E https://t.co/ds1aRzAPF7

FDA has issued its final guidance on: Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers https://t.co/69sbgoWnSW https://t.co/kpTgdPOkka

FDA has issued its final guidance on: Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers https://t.co/bjiV4S0Fur https://t.co/dDyJqhV5VF

China cross-sectional cohort study of 10658 gout pts, showed betw 2003-22, gout onset age signif declined (42 to 38.9 yrs) w/ 6% incr in ≤19 and 9.6% ince in 20–29 yrs. Younger onset also assoc w/ gout severity(tophi, flares, Kstones) & more HTN, DM, less dyslipidemia https://t.co/XczvWr0xZl

The countdown is on! ⏱️ Drs. Jack Cush & Artie Kavanaugh are previewing what’s coming to RheumNow Live 2026 in Dallas (Feb 7–8) – and you don’t want FOMO on this one. ✅ Register now at https://t.co/4UQlqwujiR 🔥Early bird pricing ends December 15 – Get the inside scoop on https://t.co/K6kxX2oDtu

APP QD Clinic: Difficult AxSpA Philip Mease, MD and Christy Vath, PA-C, Seattle discuss a difficult to treat axial spondyloarthritis (axSpA) case. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/qlBUtt6zWr

Phase 1 trial of IL-6 targeting immunotherapy (PPV-06) in 24 pts w/ inflammatory knee osteoarthritis (KOA) demonstrates safety, Abs that neutralize IL-6, decreasing CRP values and improved clinical outcomes, determined by changes in KOOS scores https://t.co/urZupN62Kw https://t.co/sru1SnsOig